ESTRO Multidisciplinary Management of Breast Cancer 2017

Dutch guideline early data

Recurrence

5

4.5

4

3.5

3

2.5

2

Note of caution: LRR was higher on subgroup analysis of younger women (<50 years) so probably NOT appropriate in this higher risk group. Longer term follow up and more data are probably needed before adoption and pathology review of each case

1.5

1

0.5

0

clear

focal positive

positive

Recurrence